Cargando…

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)

Alternative lengthening of telomeres (ALT) supports telomere maintenance in 10–15% of cancers, thus representing a compelling target for therapy. By performing anti-cancer compound library screen on isogenic cell lines and using extrachromosomal telomeric C-circles, as a bona fide marker of ALT acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusuma, Frances Karla, Prabhu, Aishvaryaa, Tieo, Galen, Ahmed, Syed Moiz, Dakle, Pushkar, Yong, Wai Khang, Pathak, Elina, Madan, Vikas, Jiang, Yan Yi, Tam, Wai Leong, Kappei, Dennis, Dröge, Peter, Koeffler, H. Phillip, Jeitany, Maya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079688/ https://www.ncbi.nlm.nih.gov/pubmed/37024489 http://dx.doi.org/10.1038/s41467-023-37633-3

Ejemplares similares

Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
por: Jeitany, Maya, et al.
Publicado: (2020)

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
por: Amorim, João P., et al.
Publicado: (2016)

Alternative lengthening of telomeres (ALT) in cancer stem cells in vivo
por: Bojovic, Bojana, et al.
Publicado: (2014)

Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells
por: Zhao, Shuang, et al.
Publicado: (2019)

The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)
por: Sohn, Eric J., et al.
Publicado: (2023)

Single-molecule analysis of subtelomeres and telomeres in Alternative Lengthening of Telomeres (ALT) cells
por: Abid, Heba Z., et al.
Publicado: (2020)

Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)
por: De Vitis, Marco, et al.
Publicado: (2018)

Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs
por: Rosso, Ilaria, et al.
Publicado: (2023)

ALT control, delete: FANCM as an anti-cancer target in Alternative Lengthening of Telomeres
por: O’Rourke, Julienne J, et al.
Publicado: (2019)

TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes
por: Armendáriz-Castillo, Isaac, et al.
Publicado: (2020)

ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats
por: Frank, Lukas, et al.
Publicado: (2022)

Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT)
por: Sun, Haolu, et al.
Publicado: (2023)

MEDB-68. Analysis of telomeres length and Alternative Lengthening of Telomeres (ALT) in molecular subgroups of infant medulloblastoma
por: Buttarelli, Francesca Romana, et al.
Publicado: (2022)

The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)
por: Lu, Robert, et al.
Publicado: (2019)

Epigenetic Characteristics of Human Subtelomeres Vary in Cells Utilizing the Alternative Lengthening of Telomeres (ALT) Pathway
por: Toubiana, Shir, et al.
Publicado: (2021)

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
por: Luchini, Claudio, et al.
Publicado: (2021)

Identification of somatic alterations in lipoma using whole exome sequencing
por: Kanojia, Deepika, et al.
Publicado: (2019)

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis
por: Lawlor, Rita T., et al.
Publicado: (2019)

Author Correction: The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)
por: Lu, Robert, et al.
Publicado: (2019)

ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells
por: Madan, Vikas, et al.
Publicado: (2021)

A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT)
por: Jeitany, Maya, et al.
Publicado: (2015)

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020)

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
por: Shyamsunder, Pavithra, et al.
Publicado: (2022)

ALT cancer cells are specifically sensitive to lysine acetyl transferase inhibition
por: Bakhos-Douaihy, Dalal, et al.
Publicado: (2019)

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
por: Falcinelli, Marta, et al.
Publicado: (2023)

Telomeres susceptibility to environmental arsenic exposure: Shortening or lengthening?
por: Wai, Kyi Mar, et al.
Publicado: (2023)

CARD10, a CEBPE target involved in granulocytic differentiation
por: Shyamsunder, Pavithra, et al.
Publicado: (2018)

Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021)

Telomere clustering drives ALT
por: Min, Jaewon, et al.
Publicado: (2019)

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner
por: Brosnan-Cashman, Jacqueline A., et al.
Publicado: (2018)

The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity
por: Chen, Yuan-Yin, et al.
Publicado: (2021)

Effects of BRCA2 deficiency on telomere recombination in non-ALT and ALT cells
por: Sapir, Ester, et al.
Publicado: (2011)

Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis
por: Madan, Vikas, et al.
Publicado: (2023)

Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice
por: Han, Lin, et al.
Publicado: (2019)

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
por: Hackeng, Wenzel M, et al.
Publicado: (2022)

Eruptive melanocytic nevi associated with ponatinib
por: Devred, Inès, et al.
Publicado: (2018)

Ponatinib-Induced Cerebrovascular Accident (CVA)
por: Azad, Farhan, et al.
Publicado: (2022)

Reengineering Ponatinib to Minimize Cardiovascular Toxicity
por: Hnatiuk, Anna P., et al.
Publicado: (2022)

Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants
por: Stundon, Jennifer L, et al.
Publicado: (2022)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8iihrdh06qa1cmdjgrbard0m4b